SynthesisScientific reports2025
The chemobrain in breast cancer patients: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bypassing Androgens: Retina-Targeted 17β-Estradiol Delivery via DHED Eye Drops Ameliorates Orchiectomy-Induced Shifts in the Male Rat Visual Cortex Proteome.Antioxidants (Basel, Switzerland) · 2026Article
- Cognitive profiles and predictors of cancer-related cognitive impairment in breast cancer survivors: integrating self-reported, neuropsychological, and process-based measures.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Working Memory Impairment Induced by Chemotherapy-A Narrative Review.Brain sciences · 2026Review
- Transcranial photobiomodulation for the treatment of chemobrain: new perspectives from a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The long road after breast cancer: survivorship issues and long-term treatment effects in young women.Frontiers in oncology · 2026Review
- Lurasidone ameliorates doxorubicin-induced chemobrain in male Wistar rats: involvement of the hippocampal and prefrontal cortex CREB/BDNF/Glt-1 axis and glutamate homeostasis.Frontiers in pharmacology · 2026Article
- Chemotherapy-related cognitive impairment as a crisis of the self: a Winnicottian psycho-oncological perspective.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to determine the incidence of chemobrain in breast cancer patients, define it, and review the various tools used to measure it. A comprehensive literature review was performed, and covered all publications up to and including September 30, 2024. Studies were eligible for inclusion if they reported data on chemobrain in adults with breast cancer receiving chemotherapy. The following data were extracted: study characteristics, information on chemobrain, and information on breast cancer treatment. A total of 287 records were identified by the literature search. After eliminating duplicates, irrelevant articles after title and abstract screening, or after full-text review, 11 records were included in the study. The incidence across studies ranged from 9.6 to 81.0%. The pooled incidence of chemobrain was estimated at 39.9% (95% CI 26.3%, 55.2%). Chemobrain appears to affect a significant proportion of breast cancer patients undergoing chemotherapy, with a pooled incidence estimate of approximately 40%. However, the wide range of reported incidences (9.6-81%) suggests that the true prevalence may vary depending on study design, definitions, and assessment tools used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.